These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38630383)

  • 1. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
    Kawakami H
    Int J Clin Oncol; 2024 Sep; 29(9):1228-1236. PubMed ID: 38630383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
    Catenacci DV; Tesfaye A; Tejani M; Cheung E; Eisenberg P; Scott AJ; Eng C; Hnatyszyn J; Marina N; Powers J; Wainberg Z
    Future Oncol; 2019 Jun; 15(18):2073-2082. PubMed ID: 31094225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
    Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
    JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2.
    Mehlhaff E; Miller D; Ebben JD; Dobrzhanskyi O; Uboha NV
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):659-675. PubMed ID: 38485551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
    Lai S; Luo S; Huang Q; Lin S; Huang X; Xue H; Cai Y; Xu X; Weng X
    Pharmacogenomics; 2024; 25(5-6):249-257. PubMed ID: 38884946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted agents for gastric and gastroesophageal junction cancer.
    Oshima T; Masuda M
    Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
    Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
    Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
    Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
    Wainberg ZA; Kang YK; Lee KW; Qin S; Yamaguchi K; Kim IH; Saeed A; Oh SC; Li J; Turk HM; Teixeira A; Hitre E; Udrea AA; Cardellino GG; Sanchez RG; Zahlten-Kümeli A; Taylor K; Enzinger PC
    Gastric Cancer; 2024 May; 27(3):558-570. PubMed ID: 38308771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
    Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
    Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.